- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03901755
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B (B-MORE)
January 31, 2024 updated by: Swedish Orphan Biovitrum
A 24-month Prospective, Non-interventional, International, Multicentre Study to Describe the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product.
The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic treatment of haemophilia B.
Study Overview
Study Type
Observational
Enrollment (Actual)
151
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brno, Czechia
- Swedish Orphan Biovitrum Research Site
-
Prague, Czechia
- Swedish Orphan Biovitrum Research Site
-
-
-
-
-
Athens, Greece
- Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital)
-
Athens, Greece
- Swedish Orphan Biovitrum Research Site (Laikο General Hospital of Athens)
-
-
-
-
-
Dublin, Ireland
- Swedish Orphan Biovitrum Research Site
-
-
-
-
-
Bari, Italy
- Swedish Orphan Biovitrum Research Site
-
Florence, Italy
- Swedish Orphan Biovitrum Research Site
-
Genova, Italy
- Swedish Orphan Biovitrum Research Site
-
Milan, Italy
- Swedish Orphan Biovitrum Research Site
-
Roma, Italy
- Swedish Orphan Biovitrum Research Site
-
Turin, Italy
- Swedish Orphan Biovitrum Research Site
-
-
-
-
-
Oslo, Norway
- Swedish Orphan Biovitrum Research Site
-
-
-
-
-
Riyadh, Saudi Arabia
- Swedish Orphan Biovitrum Research Site (King Faisal Hospital adult)
-
Riyadh, Saudi Arabia
- Swedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric)
-
-
-
-
-
Barcelona, Spain
- Swedish Orphan Biovitrum Research Site (Hospital de Vall d'Hebrón)
-
Barcelona, Spain
- Swedish Orphan Biovitrum Research Site (Hospital Sant Joan de Deu)
-
Murcia, Spain
- Swedish Orphan Biovitrum Research Site
-
Vigo, Spain
- Swedish Orphan Biovitrum Research Site
-
-
-
-
-
Gothenburg, Sweden
- Swedish Orphan Biovitrum Research Site
-
Malmö, Sweden
- Swedish Orphan Biovitrum Research Site
-
Stockholm, Sweden
- Swedish Orphan Biovitrum Research Site (Karolinska University Hospital adult)
-
Stockholm, Sweden
- Swedish Orphan Biovitrum Research Site (Karolinska University Hospital pediatric)
-
-
-
-
-
Hull, United Kingdom
- Swedish Orphan Biovitrum Research Site
-
London, United Kingdom, NW3 2QG
- Swedish Orphan Biovitrum Research Site
-
London, United Kingdom, SE1 7EH
- Swedish Orphan Biovitrum Research Site
-
London, United Kingdom, W12 0HS
- Swedish Orphan Biovitrum Research Site
-
London, United Kingdom, WC1N 3JH
- Swedish Orphan Biovitrum Research Site
-
Manchester, United Kingdom
- Swedish Orphan Biovitrum Research Site
-
Oxford, United Kingdom
- Swedish Orphan Biovitrum Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All eligible patients who present for a routine Clinical visit will be asked to participate in the study by the treating physician at participating haemophilia treatment centres.
Description
Inclusion Criteria:
- Have a diagnosis of haemophilia B
- Have started Alprolix treatment prior to enrolment visit, or at enrolment prescribed treatment with Alprolix irrespective of participation in the study
- Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations.
Exclusion Criteria:
- Participation in an investigational medicinal product trial at enrolment visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prophylactic patients
Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
|
Extended half-life factor IX product
Other Names:
|
On demand patients
Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
|
Extended half-life factor IX product
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Annualised bleeding rate (ABR)
Time Frame: 24 months
|
Bleeding episodes assessed according to local practice
|
24 months
|
Annualised injection frequency
Time Frame: 24 months
|
Assessed by prescription
|
24 months
|
Annualised factor consumption
Time Frame: 24 months
|
Assessed by dispensed factor product
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Elena Santagostino, MD, Swedish Orphan Biovitrum
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2019
Primary Completion (Estimated)
May 31, 2024
Study Completion (Estimated)
May 31, 2024
Study Registration Dates
First Submitted
April 2, 2019
First Submitted That Met QC Criteria
April 2, 2019
First Posted (Actual)
April 3, 2019
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sobi.Alprolix-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia B
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
BayerCompletedHemophilia A; Hemophilia BIsrael
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
American Thrombosis and Hemostasis NetworkGenentech, Inc.Active, not recruitingHemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
University College, LondonRecruiting
-
University of British ColumbiaBiogenCompletedHemophilia A, Congenital | Hemophilia B, CongenitalCanada
-
Laboratoire français de Fractionnement et de BiotechnologiesLFB USA, Inc.CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With InhibitorsBulgaria, Ukraine, Czechia, United States, Georgia, South Africa
-
Suzhou Alphamab Co., Ltd.RecruitingHemophilia A With Inhibitor | Hemophilia B With InhibitorChina
-
AryoGen Pharmed Co.CompletedHemophilia A With Inhibitor | Hemophilia B With InhibitorIran, Islamic Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHemophilia A With Inhibitor | Hemophilia B With InhibitorChina
Clinical Trials on Alprolix
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia BUnited States, Switzerland, Germany
-
Swedish Orphan BiovitrumCerner EnvizaCompleted
-
Bioverativ, a Sanofi companySwedish Orphan BiovitrumCompletedHemophilia BUnited States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
-
Bioverativ Therapeutics Inc.Swedish Orphan Biovitrum; Syntonix Pharmaceuticals, Inc.Completed
-
Bioverativ Therapeutics Inc.CompletedSevere Hemophilia BUnited States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
-
Swedish Orphan BiovitrumCompletedHaemophilia A | Haemophilia BGermany
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumCompletedHemophilia BUnited States, United Kingdom, South Africa, Netherlands, Ireland, Australia
-
Emory UniversityBioverativ Therapeutics Inc.CompletedHemophilia | Menstrual Flow ExcessiveUnited States
-
Hospices Civils de LyonRecruiting
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumTerminatedHemophilia A | Hemophilia BUnited States